Cargando…

Off-label therapy targeting pathogenic inflammation in COVID-19

Detalles Bibliográficos
Autores principales:	Romani, Luigina, Tomino, Carlo, Puccetti, Paolo, Garaci, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290072/ https://www.ncbi.nlm.nih.gov/pubmed/32547788 http://dx.doi.org/10.1038/s41420-020-0283-2

Ejemplares similares

Evaluating interest in off-label use of disinfectants for COVID-19
por: Rivera, Jessica Malaty, et al.
Publicado: (2020)

Defective Glyoxalase 1 Contributes to Pathogenic Inflammation in Cystic Fibrosis
por: Pariano, Marilena, et al.
Publicado: (2021)

Comment: Is off-label medication use in the ICU a problem?
por: Cotta, Menino O., et al.
Publicado: (2023)

Therapeutic dilemmas in dialysis patients hospitalized for COVID-19: balancing between nihilism, off-label treatment and side effects
por: Kusztal, Mariusz, et al.
Publicado: (2021)

Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
por: Shapiro, Adrienne E, et al.
Publicado: (2022)

Editorial: From microbial immunology to microbial therapeutics via targeted delivery technology
por: Puccetti, Matteo, et al.
Publicado: (2022)

Long COVID: systemic inflammation and obesity as therapeutic targets
por: Florencio, Lidiane L, et al.
Publicado: (2022)

Is neutrophilic inflammation treatable in COVID-19?
por: Conrad, Catharina, et al.
Publicado: (2022)

Is IL-6 a key cytokine target for therapy in COVID-19?
por: Jones, Simon A., et al.
Publicado: (2021)

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
por: Saini, Kamal S., et al.
Publicado: (2020)

A Reappraisal of Thymosin Alpha1 in Cancer Therapy
por: Costantini, Claudio, et al.
Publicado: (2019)

COVID-19 and beyond: Reassessing the role of thymosin alpha1 in lung infections
por: Bellet, Marina M., et al.
Publicado: (2023)

CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo
por: Aryal, Neeraj K, et al.
Publicado: (2018)

Complement as a target in COVID-19?
por: Risitano, Antonio M., et al.
Publicado: (2020)

Passive antibody therapy in COVID-19
por: Abraham, Jonathan
Publicado: (2020)

Emerging mechanisms and novel targets in allergic inflammation and asthma
por: Weiss, Scott T.
Publicado: (2017)

Viral arthritis and COVID-19
por: Parisi, Simone, et al.
Publicado: (2020)

Hypothesis-driven genomics pays off
por: Petsko, Gregory A
Publicado: (2012)

Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. J. Pers. Med. 2023, 13, 553
por: Graziosi, Luigina, et al.
Publicado: (2023)

COVID-19: immunopathology and its implications for therapy
por: Cao, Xuetao
Publicado: (2020)

Intravenous immunoglobulin therapy for COVID-19 ARDS
por: Wilfong, Erin M, et al.
Publicado: (2022)

COVID-19 cytokine storm: targeting the appropriate cytokine
por: Cron, Randy Q
Publicado: (2021)

Disease Tolerance Mediated by Phosphorylated Indoleamine-2,3 Dioxygenase Confers Resistance to a Primary Fungal Pathogen
por: de Araújo, Eliseu Frank, et al.
Publicado: (2017)

Recovery from mRNA COVID-19 vaccine-related myocarditis
por: Ammirati, Enrico, et al.
Publicado: (2022)

Electroconvulsive therapy practice during the COVID-19 pandemic
por: Bellini, Helena, et al.
Publicado: (2020)

Convalescent plasma as a potential therapy for COVID-19
por: Chen, Long, et al.
Publicado: (2020)

Kidney involvement in COVID-19 and rationale for extracorporeal therapies
por: Ronco, Claudio, et al.
Publicado: (2020)

COVID-19 and systemic anticancer therapy: exploiting uncertainty
por: Gelderblom, Hans, et al.
Publicado: (2021)

CD24Fc: an emerging COVID-19 therapy
por: Eckhardt, Christina M, et al.
Publicado: (2022)

No perfect therapy for the imperfect COVID-19 cytokine storm
por: Cron, Randy Q
Publicado: (2022)

COVID-19: ACT trials for colchicine and antithrombotic therapies
por: Barco, Stefano, et al.
Publicado: (2022)

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
por: Schett, Georg, et al.
Publicado: (2020)

Loneliness and negative effects on mental health as trade-offs of the policy response to COVID-19
por: Popa, Elena
Publicado: (2021)

The opening salvo of anti-complement therapy against COVID-19
por: Campbell, Courtney M
Publicado: (2020)

Challenges in lung cancer therapy during the COVID-19 pandemic
por: Calabrò, Luana, et al.
Publicado: (2020)

Who, what, and when—effective therapy for severe COVID-19
por: Kelmenson, Daniel A, et al.
Publicado: (2022)

Brain Leukocytes as the Potential Therapeutic Target for Post-COVID-19 Brain Fog
por: Kazama, Itsuro
Publicado: (2023)

COVID-19 and liver disease: where are we now?
por: Russo, Francesco Paolo, et al.
Publicado: (2022)

Is calorie labelling on menus the solution to obesity?
por: Yeo, Giles S. H.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein S1 Induces Methylglyoxal-Derived Hydroimidazolone/Receptor for Advanced Glycation End Products (MG-H1/RAGE) Activation to Promote Inflammation in Human Bronchial BEAS-2B Cells
por: Manfredelli, Dominga, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8g5vc7373ktdfqugjoqc7v5r0c